20

CLAIMS

- 1. A pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the functions of midkine (MK) as an effective ingredient.
- 2. The pharmaceutical composition of claim 1, wherein the compound inhibiting the function of MK is an antisense oligonucleotide that inhibits intracellular MK protein synthesis by binding to a segment of a single-stranded mRNA transcribed from the MK gene.
- 10 3. The pharmaceutical composition of claim 1, wherein the compound inhibiting the function of MK is an antibody against the MK protein or a fragment comprising its variable region.
 - 4. The pharmaceutical composition of claim 1, wherein angiostenosis is caused by arteriosclerosis or restenosis after PTCA surgery.
- 15 5. A method for screening a compound for the prevention or treatment of angiostenosis, comprising the steps of:
 - (a) contacting MK expressed cells with a candidate compound; and,
 - (b) selecting a compound inhibiting the function of MK.
 - 6. A pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound selected by the method of claim 5 as an effective ingredient.

Add A